Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies

Hepatitis B virus (HBV) infection is the most important cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide.1 In high-income settings, between 5 and 10% of HIV-infected individuals are coinfected with HBV, which is a major cause of severe morbidity and mortality in this population.2 HIV infection accelerates the progression of HBV-related liver disease and mortality is higher among HIV/HBV-coinfected individuals compared to HBV-monoinfected ones.3 While the incidence of HBV-related HCC is estimated to range between 0.1 and 0.4% per year among non-cirrhotics and to be above 3% per year among cirrhotics, it is uncertain if the risk of developing HCC is different among HIV/HBV-coinfected individuals.

Source: Journal of Hepatology - June 2, 2019 Category: Gastroenterology Authors: Gilles Wandeler, Etienne Mauron, Andrew Atkinson, Jean-Fran çois Dufour, David Kraus, Peter Reiss, Lars Peters, François Dabis, Jan Fehr, Enos Bernasconi, Marc van der Valk, Colette Smit, Lars K. Gjærde, Jürgen Rockstroh, Didier Neau, Fabrice Bonnet, Source Type: research